Shifeng Lou

Shifeng Lou


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Open access
YLYifei Li
Yifei Li
SYShiyi Yuan
Shiyi Yuan
WWWu Wu
Wu Wu
JZJingwen Zhou
Jingwen Zhou
PZPing Zhang
Ping Zhang
SLShifeng Lou
Shifeng Lou
Aberrant lipid metabolism is a hallmark of malignant cancers. Recent studies have shown that abnormal activation of the lipolysis pathway might contribute to acute myeloid leukemia (AML) progression. However, the molecular mechanism through which lipid metabolism mediates AML progression is unknown. RNA-sequencing was used to screen out the target gene pnpla2/ATGL(adipose triglyceride lipase), which showed differential expression in AML. A comparison was made of ATGL mRNA levels in different AML cell lines by real-time PCR. ATGL expression was blocked using siRNAs, and then ATGL expression, proliferation, apoptosis, and cell cycle progression of si-ATGL AML cell lines and si-control AML cell lines were respectively tested. Online tools were used to analyze the potential target microRNAs of ATGL. The mechanism through which hsa-miR-214-3p regulates ATGL was detected by western blotting, proliferation assays, flow cytometry, and dual-luciferase reporter assays. Our results showed that ATGL was overexpressed in AML cell lines. Moreover, ATGL promoted the growth of AML cells. Additionally, hsa-miR-214-3p could suppress ATGL. Finally, we show that hsa-miR-214-3p regulates ATGL through the hsa-miR-214-3p/ATGL/PPARα pathway. This study showed that hsa-miR-214-3p-regulates aberrant lipolysis by promoting ATGL expression, which causes AML progression through the PPARα pathway.

17 June 2023 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
TXTAN XU
TAN XU
XWXiaoqi Wang
Xiaoqi Wang
CZChenhong Zhang
Chenhong Zhang
XZXian-Lan Zhao
Xian-Lan Zhao
HYHan Yao
Han Yao
SLShifeng Lou
Shifeng Lou


1 January 2023 in Diseases & Research
Verified
Journal Article
Open access
PDF file
LSLuo Siqi
Luo Siqi
RHRong Huang
Rong Huang
SLShifeng Lou
Shifeng Lou
Multiparameter flow cytometry (MFC) shows promise in the diagnosis and differential diagnosis of myelodysplastic neoplasms (MDS). By identifying abnormal immunophenotypes of different cell lineages in bone marrow (BM) cells, MFC can aid in the differential diagnosis of some bone marrow failure diseases. Several flow cytometry scoring systems have been established based on current parameters, but there is still no specific immunophenotype available for the diagnosis of MDS. Morphological examination of cells remains the gold standard for MDS diagnosis. In the future, identifying specific cell immunophenotypes may improve MDS diagnosis and alter the use of MFC. MFC may also provide a solution for tracking the evolution of specific abnormal hematopoietic clones in MDS.